WO2017073849A1 - 톱니모자반 추출물을 유효성분으로 포함하는 관절염 예방 또는 치료용 조성물 - Google Patents
톱니모자반 추출물을 유효성분으로 포함하는 관절염 예방 또는 치료용 조성물 Download PDFInfo
- Publication number
- WO2017073849A1 WO2017073849A1 PCT/KR2016/001371 KR2016001371W WO2017073849A1 WO 2017073849 A1 WO2017073849 A1 WO 2017073849A1 KR 2016001371 W KR2016001371 W KR 2016001371W WO 2017073849 A1 WO2017073849 A1 WO 2017073849A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- arthritis
- sawtooth
- present
- mavan
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
Definitions
- the present invention relates to a composition for the prevention or treatment of arthritis comprising the sawtooth mavan extract as an active ingredient.
- the body consists of about 200 joints. Joints are areas where bones meet. Joints are composed of cartilage, articular capsule, synovial cord, ligaments, tendons, muscles, etc., so that the bones can move smoothly between the bones and absorb the shock generated by the movement.
- Inflammatory diseases in these joints include chronic joint rheumatism, which is believed to be caused by autoimmunity, infectious arthritis caused by bacterial infections, degenerative arthritis that causes degeneration or destruction of joint cartilage or bone due to various causes, and degenerative changes in connective tissue.
- Soluble metabolites can be broadly classified into crystalline arthritis and the like deposited as crystals in connective tissue around the joint.
- Degenerative arthritis causes degeneration of chondrocytes constituting the joint due to aging, which inhibits the synthesis of type II collagen and proteoglycan, which are the matrix substances of the joint, in chondrocytes.
- type II collagen and proteoglycan which are the matrix substances of the joint, in chondrocytes.
- inflammatory cytokines such as interleukin-1 ⁇ and tumor necrosis factor- ⁇ are produced, the synthesis of matrix metalloproteinase (MMP), which degrades articular substrates, It is a disease caused by the destruction of joint tissue due to increased activity in joint cells.
- MMP matrix metalloproteinase
- arthritis is further exacerbated by the production of nitrogen monoxide by inflammatory cytokines and the production of self-amplifying cytokines by the produced nitrogen monoxide, leading to the synthesis of more MMPs, thereby promoting the degradation of articular substrates.
- inflammatory cytokines increase the production of the lipid metabolite, prostaglandin E2, causing an inflammatory response in arthritis.
- the inflammatory response involves various biochemical phenomena, and in particular, the reaction is initiated or regulated by various enzymes related to the inflammatory response produced by immune cells.
- the immune cells move to damaged sites through blood vessels with the help of histamine, nitric oxide (NO) or prostaglandin E2 (PGE2) to initiate an inflammatory response.
- Immune cells migrated to the damaged site were cytokines such as tumor necrosis factor- ⁇ , interleukin-1 ⁇ , or interleukin-6, MIP-1, IL Chemokines such as -8 or MCP-1 secrete chemokine to destroy direct external invaders or other immune cells to initiate an inflammatory response.
- Inflammatory substances such as interferon- ⁇ , lipoteichoic acid, and lipopolysaccharide (LPS), which cause the inflammatory response, or when exposed to various inflammation-inducing cytokines, iNOS (inducible Nitric Oxide synthase) and COX-2 (cyclooxygenase-2) is expressed, producing excess NO and PGE2.
- iNOS inducible Nitric Oxide synthase
- COX-2 cyclooxygenase-2
- Many of these inflammatory initiators iNOS, COX-2, TNF- ⁇ , IL-6, etc.
- NF- ⁇ B When NO is produced more than necessary, vasodilation by shock, It causes tissue damage, mutagenesis, and nerve tissue damage caused by inflammatory reactions.
- Nitric oxide is made by L-arginine and molecular oxygen by NO synthase (NOS).
- NOS NO synthase
- nNOS and eNOS are constitutively expressed in neutrophils and endothelial cells.
- iNOS is inducibly produced in macrophages or monocytes by exposure to LPS or the pro-inflammatory cytokine (Vane et al., 1994).
- NO produced in iNOS acts as a proliferation inhibitor or cytotoxic agent of pathogens that invade cells by causing inflammation or immune response.
- NF- ⁇ B Nuclear factor kappa B
- NF- ⁇ B activation promotes the expression of iNOS and several proinflammatory genes (Kim et al., 2005; Makarov, 2001).
- the activation pathway of NF- ⁇ B is the phosphorylation of inhibitor of kB (I ⁇ B) - ⁇ kinase by LPS followed by phosphorylation of I ⁇ B- ⁇ and degradation of I ⁇ B- ⁇ , which is phosphorylated by ubiquitine, to move free NF-kB to the nucleus.
- I ⁇ B inhibitor of kB
- MAPKs mitogen-activated protein kinases
- PI3K phosphatidylinositol 3-kinase
- Akt protein kinase B pathway
- MAPKs include extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38 MAPK, which are involved in the transcriptional regulation of inflammatory genes through NF- ⁇ B activation (Bhat et al., 1998 Kao et al., 2005; Shin et al., 2010).
- PI3K is also involved in the production of inflammatory cytokines through NF-kB activation (Cremer et al., 2011; Sheu et al., 2005).
- PI3K activation phosphorylates phosphatidylinositide to activate Akt protein.
- Activated PI3K / Akt plays a major role in the activation of macrophages (MacMicking et al., 1997; Sheu et al., 2005). Therefore, in order to develop an anti-inflammatory agent, many studies have been conducted to find a substance that inhibits the activation of NK-kB or inhibits the activation of MAPKs and Akt that activates NF-kB.
- MMPs are proteolytic enzymes that destroy the matrix components of bone and cartilage, and are expressed in cartilage tissue stimulated by inflammatory cytokines during inflammatory diseases, increasing their activity.
- MMPs comprise at least 21 enzymes: collagenase (MMP-1,8,13), stromelysin (MMP-3,10,11), gelatinase (MMP-2,9), and matrix type-1 metalloproteinase (MMP-14).
- MMP-1,8,13 collagenase
- MMP-3,10,11 stromelysin
- MMP-2,9 matrix type-1 metalloproteinase
- MMP-14 matrix type-1 metalloproteinase
- MMP-2 and MMP-9 are gelatinase subfamily, which is an important enzyme for collagen breakdown of cartilage tissue. Both enzymes degrade other substrates, including fibrous collagen I and II and aggrecan, which are present in large amounts in cartilage.
- Rheumatoid and degenerative arthritis are characterized by inflammatory cell infiltration into the synovial tissue of the joint, which is mediated by chemokine.
- Chemokines such as monocyte chemoattractant protein-1 (MCP-1) are expressed in the synovial tissue of arthritis, and these are known to be produced in synovial fibroblasts. Excess MCP-1 produced by arthritis induces monocytes and macrophages into the inflammatory site, and activates these cells to promote the production of inflammatory cytokines, thereby acting to worsen inflammation.
- MCP-1 monocyte chemoattractant protein-1
- Cytokines in the synovial tissue of rheumatoid and degenerative arthritis stimulate the expression of adhesion molecules such as vascular cellular adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1) and E-selectin in vascular endothelial cells. Increase to induce infiltration of inflammatory cells. Overexpressed ICAM-1 and VCAM-1 are associated with chronic inflammation, such as rheumatoid arthritis and degenerative arthritis.
- Rheumatoid and degenerative arthritis are chronic systemic inflammatory diseases that cause symmetry and multiple arthritis, resulting in joint damage and deformation. When not treated for such arthritis, the progress is poor, indicating a disorder of joint function, and if further persisted, it interferes with daily life due to the disorder of joint function. It is estimated that about 1% of the population in Korea is suffering from rheumatoid arthritis. The incidence of rheumatoid arthritis is three times higher in women than in men, and it is known to occur mainly in the 20s and 40s.
- Autoimmunity is a phenomenon in which chronic inflammation occurs in various parts of the body continuously and continuously due to abnormal immune control function of our body.
- the drugs used to treat arthritis may be classified based on the main mechanism of action, such as a decrease in inflammation, a delay in disease progression, and a decrease in uric acid concentration.
- Many drugs for treating arthritis reduce inflammation. Inflammation is a pathological process that causes pain, swelling, heat, seizures, and stiffness.
- Drugs that relieve inflammation rapidly include nonsteroidal anti-inflammatory drugs, including aspirin, and steroidal anti-inflammatory drugs, including cortisone.
- Non-steroidal anti-inflammatory drugs can reduce pain and relax the nerve joints and relieve inflammation, but can also cause gastrointestinal upsets and abdominal pain, so people with active peptic ulcers or hemorrhagic history of the gastrointestinal tract Use is prohibited. Steroidal anti-inflammatory drugs are not used for degenerative neuroarthritis due to their serious side effects such as weight gain and high blood pressure.
- steroidal anti-inflammatory drugs have nothing to do with treating the cause of the disease, and may simply reduce pain temporarily, leading to overuse of the joint, which can destroy nerve joints and worsen disorders. Requires attention.
- the present inventors have confirmed that the sawtooth maban inhibits inflammatory cytokines and improves arthritis in arthritis experimental animals, thereby confirming that it can be used as a therapeutic agent for arthritis and completed the present invention.
- a pharmaceutical composition for preventing or treating arthritis which includes Sawtooth Mavan extract ( Sargassum serratifolium ) as an active ingredient.
- Another object of the present invention is to provide a health functional food for preventing or improving arthritis, including sawtooth mavan extract ( Sargassum serratifolium ) as an active ingredient.
- sawtooth mavan extract Sargassum serratifolium
- the present invention is sawtooth mavan extract Sargassum Serratifolium ) provides a pharmaceutical composition for preventing or treating arthritis comprising as an active ingredient.
- the sawtooth mavan extract may be an extract obtained using water or an organic solvent.
- the organic solvent may be selected from the group consisting of methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane and cyclohexane.
- the sawtooth mavan extract can reduce or inhibit the activity of the inflammatory cytokines IL-1 ⁇ , IL-6 or TNF-a.
- the arthritis may be degenerative arthritis, rheumatoid arthritis or lupus arthritis.
- the present invention is sawtooth mavan extract Sargassum Serratifolium ) provides a dietary supplement for the prevention or improvement of arthritis comprising as an active ingredient.
- the present invention relates to a composition for the prevention or treatment of arthritis comprising the sawtooth mavan extract as an active ingredient.
- Sawtooth Mavan extract according to the present invention is excellent in reducing or inhibiting the activity of the inflammatory cytokines IL-1 ⁇ , IL-6 or TNF-a, and excellent in improving arthritis in arthritis animal models, the composition for treating arthritis It can be usefully used.
- Figure 1 shows the results of measuring the cytotoxicity to the cells after the treatment of the alcohol extract (EtOH) of the sawtooth maban by concentration.
- Figure 2 is a schematic diagram showing the production process of rheumatoid arthritis experimental animal model.
- Figure 3 shows the result of confirming the weight change for 6 weeks after administration of the sawtooth mavan extract of the present invention to rheumatoid arthritis experimental animals.
- Figure 4 is a result of confirming the change in foot thickness after administration of the sawtooth mavan extract of the present invention to rheumatoid arthritis experimental animals.
- Figure 7 is a result of confirming the degree of arthritis with the naked eye after administration of the sawtooth capillary extract of the present invention to rheumatoid arthritis experimental animals.
- FIG. 8 shows the degree of inhibition of the production of inflammatory cytokines (IL-1 ⁇ , IL-6 or TNF-a) in the serum after sacrificing the experimental animals at 6 weeks after administration of the sawtooth mavan extract of the present invention to rheumatoid arthritis experimental animals. The result is.
- IL-1 ⁇ , IL-6 or TNF-a inflammatory cytokines
- Figure 9 shows the degree of inhibition of the production of inflammatory cytokines (IL-1 ⁇ , IL-6 or TNF-a) in the hind paw tissue after sacrificing the test animals 6 weeks after administration of the sawtooth mavan extract of the present invention to rheumatoid arthritis experimental animals. This is confirmed by Western blot.
- IL-1 ⁇ , IL-6 or TNF-a inflammatory cytokines
- 11 is a result of confirming the degree of suppression of expression of proinflammatory proteins (iNOS, COX-2) in the hind paw tissue after sacrifice of the experimental animals 6 weeks after administration of the sawtooth mavan extract of the present invention to rheumatoid arthritis experimental animals.
- proinflammatory proteins iNOS, COX-2
- FIG. 12 shows the degree of phosphorylation of NF-kB, which is responsible for transcriptional regulation of proinflammatory proteins and cytokines in hind paw tissue, after sacrifice of the experimental animals 6 weeks after administration of the sawtooth mavan extract of the present invention to rheumatoid arthritis experimental animals. The result is.
- FIG. 13 is a top protein involved in the activation of NF-kB, a transcription factor that modulates inflammation in hind paw tissue after 6 weeks after sacrifice of the sawtooth mavan extract of the present invention to rheumatoid arthritis experimental animals (Akt, JNK, p38 protein) is the result of checking the degree of phosphorylation.
- the present invention relates to a novel use of the sawtooth mavan extract, which has been found to have excellent arthritis therapeutic activity in the sawtooth mavan extract.
- the sawtooth mavan extract which is a perennial large brown alga that is 1 to 4 m as a plant that grows in the intertidal zone over lunch.
- Roots are 4 ⁇ 5cm in diameter, conical, rubbery, with rings, stems are circumferential, short, divided into a number of central branches, and pressed.
- both edges of the stem are thin, vertically ridged to one side, with short branches at the edges, the stem leaves toward the base, with double teeth on the edge, and the bubble is round and close to the top.
- House or spiny spines In particular, it is known to grow on the southern coast of Korea and Jeju, and it is known to have a function of lipid lowering, blood pressure lowering, and radioisotope emission, and there is no known effect related to arthritis.
- the sawtooth mavan extract has therapeutic activity for arthritis, according to an embodiment of the present invention, the degree of inflammatory cytokine expression associated with arthritis according to the sawtooth mavan extract treatment
- inflammatory cytokines increased rapidly in the experimental animal group induced by rheumatoid arthritis, but inflammatory cytokine expression to TNF- ⁇ , IL-6 or IL-1 ⁇ was significantly increased in the sawtooth mavan extract treatment group. It can be seen that it is suppressed.
- the sawtooth mavan extract treatment can improve the arthritis of rheumatoid arthritis experimental animals.
- the present inventors have found that the sawtooth mavan extract has therapeutic activity against arthritis, and the sawtooth mavan extract exhibits superior anti-arthritis therapeutic activity compared to other mother extracts. Therefore, the present inventors have found that the saw tooth hatch of the present invention is a more useful material for treating arthritis than other mother disease species.
- composition comprising the sawtooth mavan extract of the present invention as an active ingredient can effectively prevent or treat arthritis.
- arthritis refers to degenerative arthritis, rheumatoid arthritis, or lupus arthritis, but is not limited thereto, and most preferably, rheumatoid arthritis and degenerative arthritis.
- the sawtooth mavan may be obtained by extraction and separation from nature using extraction and separation methods known in the art, and the 'extract' defined in the present invention may be obtained from the sawtooth mavan using an appropriate solvent. It is extracted, and for example, may include all of the hot water extract, polar solvent soluble extract or non-polar solvent soluble extract of the sawtooth cap.
- any solvent that is acceptable in the art may be used, and water or an organic solvent may be used.
- Solvents such as benzene, chloroform, ethyl acetate, methylene chloride, hexane and cyclohexane may be used alone or in combination. It is not limited.
- any one of hot water extraction method, cold leaching extraction method, reflux cooling extraction method, solvent extraction method, steam distillation method, ultrasonic extraction method, elution method and compression method can be used.
- the desired extract may further be subjected to a conventional fractionation process, it may be purified using conventional purification methods.
- any known method may be used.
- the sawtooth mavan extract included in the composition of the present invention may be prepared in a powder state by an additional process such as distillation under reduced pressure, freeze drying or spray drying, which is extracted by the hydrothermal extraction or solvent extraction method described above.
- the primary extract may be further purified using various chromatography such as silica gel column chromatography, thin layer chromatography, high performance liquid chromatography, and the like. You can also get
- the sawtooth mavan extract is a concept including all the extracts, fractions and purified products obtained in each step of extraction, fractionation or purification, their dilutions, concentrates or dried products.
- composition of the present invention comprising such a sawtooth mavan extract as an active ingredient may be a pharmaceutical composition.
- the pharmaceutical composition of the present invention may be prepared using a pharmaceutically suitable and physiologically acceptable adjuvant in addition to the active ingredient, and the adjuvant may include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, Lubricants, flavors and the like can be used.
- the pharmaceutical composition may be preferably formulated into a pharmaceutical composition including one or more pharmaceutically acceptable carriers in addition to the above-described active ingredient for administration.
- Formulation forms of the pharmaceutical composition may be granules, powders, tablets, coated tablets, capsules, suppositories, solutions, syrups, juices, suspensions, emulsions, drops or injectable solutions.
- the active ingredient may be combined with an oral, nontoxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
- suitable binders, lubricants, disintegrants and coloring agents may also be included in the mixture.
- Suitable binders include but are not limited to natural and synthetic gums such as starch, gelatin, glucose or beta-lactose, corn sweeteners, acacia, trackercance or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride and the like.
- Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
- Acceptable pharmaceutical carriers in compositions formulated in liquid solutions are sterile and physiologically compatible, including saline, sterile water, Ringer's solution, buffered saline, albumin injectable solutions, dextrose solution, maltodextrin solution, glycerol, ethanol and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers and bacteriostatic agents may be added as necessary. Diluents, dispersants, surfactants, binders and lubricants may also be added in addition to formulate into injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Furthermore, the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA can be formulated according to each disease or component, as appropriate in the art.
- the sawtooth mavan extract of the present invention may be included in 0.001 to 20% by weight relative to the total weight of the composition.
- the composition of the present invention may also be a food composition, such a food composition is effective
- various flavors, natural carbohydrates, and the like may be contained as additional components, as in general food compositions.
- Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
- the aforementioned flavoring agents can advantageously be used natural flavoring agents (tautin), stevia extracts (for example rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.).
- the food composition of the present invention may be formulated in the same manner as the pharmaceutical composition, used as a functional food, or added to various foods.
- Foods to which the composition of the present invention may be added include, for example, beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gums, candy, ice creams, alcoholic beverages, vitamin complexes, and health supplements. There is this.
- the food composition is a nutrient, vitamins, minerals (electrolytes), synthetic flavors and natural flavoring agents, colorants and neutralizing agents (cheese, chocolate, etc.), pectic acid and its Salts, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks and the like.
- the food composition of the present invention may contain a fruit flesh for producing natural fruit juice and fruit juice beverage and vegetable beverage.
- the sawtooth mavan extract is a natural substance and has almost no toxicity and side effects, so it can be used safely even for long-term administration for the purpose of preventing and treating arthritis.
- the health functional food of the present invention may be prepared and processed in the form of tablets, capsules, powders, granules, liquids, pills and the like for the purpose of preventing and treating arthritis.
- health functional food refers to a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body according to the Health Functional Food Act No. 6767, and nutrients for the structure and function of the human body. It is meant to be consumed for the purpose of regulating or obtaining a useful effect for health use such as physiological action.
- the health functional food of the present invention may include a conventional food additive, and the suitability as a food additive, unless otherwise specified, in accordance with the General Regulations of the Food Additives and General Test Methods approved by the Food and Drug Administration, etc. Judging by the standards and standards.
- Food Additive Reduction examples include chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; Natural additives such as dark blue pigment, licorice extract, crystalline cellulose, high color pigment and guar gum; And mixed preparations such as sodium L-glutamate, algae additives, preservatives and tar dyes.
- a dietary supplement in the form of tablets is a mixture of a sawtooth mavan extract, an active ingredient of the present invention, with an excipient, a binder, a disintegrant, and other additives, and then granulated in a conventional manner, and then compressed with a lubricant and the like.
- the mixture can be directly compression molded.
- the health functional food in the form of tablets may contain a mating agent or the like as necessary.
- Hard capsules among the health functional foods in the form of capsules can be prepared by filling a mixture of additives, such as excipients, sawtooth mavan extract, which is an active ingredient of the present invention, into a conventional hard capsule, and soft capsules such as excipients such as excipients
- the mixture mixed with the additive of may be prepared by filling in a capsule base such as gelatin.
- the soft capsule agent may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, as necessary.
- the health functional food in the form of a cyclic form may be prepared by molding a mixture of a sawtooth mavan extract, an active ingredient of the present invention, an excipient, a binder, a disintegrant, and the like by using a conventionally known method. It may be avoided, or the surface may be coated with materials such as starch, talc.
- the health functional food in the form of granules can be prepared into a granular mixture of a sawtooth mavan extract, an active ingredient of the present invention, an excipient, a binder, a disintegrant, and the like by a conventionally known method. And the like.
- the health functional food may be beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gum, candy, ice cream, alcoholic beverages, vitamin complexes and health supplements.
- the sawtooth mavan used in the present invention was collected and used in Gijang-gun, Busan, and the spirit extract of the sawtooth mavan was obtained by the following method.
- 2 kg of powder and alcohol (95% ethanol) obtained by natural drying after drying the sawn hatch in the shade or sunny place for the manufacture of alcohol extracts were added three times at 70 ° C. for 3 hours and equipped with a reflux cooler.
- the ultrafiltration unit MWCO, 50 kDa
- the inventors of the present invention first to prepare a test animal induced rheumatoid arthritis in order to determine whether the extract can treat rheumatoid arthritis.
- the male DBA / 1J mouse (8 weeks old) was used to purify and breed for 1 week. After one week, DBA / 1J mice were treated with Complete Freund's Adjuvant (CFA) and Type 2 collagen (2 mg / mL). Mix and emulsify to form emulsion (CII / CFA). 100 ⁇ l of CII / CFA was injected subcutaneously by finding a vein in the lower part of the tail about 2-3 cm from the tail of DBA / 1J mice.
- CFA Complete Freund's Adjuvant
- Type 2 collagen 2 mg / mL
- the body weights were measured weekly for up to 7 weeks in the control group treated with nothing, the arthritis animal group (CIA treated group), and the arthritis experimental animals treated with 0.01% and 0.05% of the sawtooth mavan extract. There was a slight increase in body weight at the 3rd and 4th week, but there was no significant change in body weight. (See Figure 3).
- the present inventors measured the change in paw thickness, which is an index of arthritis, in order to confirm the therapeutic effect of rheumatoid arthritis by sawtooth moths extract.
- the arthritis-induced experimental animals increased the foot thickness due to inflammation, whereas the foot thickness of the sawtooth mavan extract treatment group was significantly reduced compared to the arthritis-induced experimental animals group. After that, it was confirmed that the thickness was similar to the control group (see FIG. 4).
- the present inventors observed the arthritis index with the naked eye in order to confirm the therapeutic effect of rheumatoid arthritis of the sawtooth mavan extract, arthritis index for each scored from 0 to 4 points, was measured by five non-testers.
- the arthritis index was high in the arthritis-induced experimental animal group, but the arthritis evaluation index was significantly higher in the treatment group treated with the sawtooth mosaic extract of the present invention. It can be seen that the lower (see Figure 5).
- the present inventors weighed the spleen to determine whether the sawtooth mavan extract can cure rheumatoid arthritis.
- the spleen is a major tissue of the human immune system, and its relative weight is often used as a preliminary indicator to assess the immunomodulatory activity of the sample to be tested.
- the present inventors visually observed the degree of arthritis treatment according to the treatment of the sawtooth mavan extract, the hind feet were severely swollen in the arthritis-induced experimental animal group, and showed erythema symptoms. However, in the treated group treated with 0.01%, 0.05% of the sawtooth mavan extract of the present invention for 19 days, it was confirmed that the swelling was reduced and erythema symptoms were alleviated (see FIG. 7).
- inflammatory mediators such as interleukin (IL) and PGE 2 are released into joints and blood by activated immune cells that gather in the inflammatory area, especially TNF- ⁇ , IL-6, IL. -1 ⁇ can be used as an indicator to determine the degree of disease of rheumatoid arthritis.
- IL interleukin
- PGE 2 activated immune cells that gather in the inflammatory area
- TNF- ⁇ , IL-6, IL. -1 ⁇ can be used as an indicator to determine the degree of disease of rheumatoid arthritis.
- the present inventors measured by using an ELISA kit to measure the expression level of the inflammatory cytokine in the blood of the experimental animal, the inflammatory cytokine was rapidly increased in the experimental animal group induced by rheumatoid arthritis, but sawtooth mavan extract of the present invention It was found that the inflammatory cytokine expression to TNF- ⁇ , IL-6 or IL-1 ⁇ was significantly inhibited in the treatment group fed a 19 days (see FIG. 8).
- the present inventors measured by Western blot in order to measure the level of inflammatory cytokine expression in the protein extracted by grinding the hind paw as an inflammation site.
- the inflammatory cytokine was rapidly increased in the experimental animal group induced by rheumatoid arthritis, but the inflammatory cytokine expression to TNF- ⁇ , IL-6 or IL-1 ⁇ was significantly increased in the sawtooth mavan extract treatment group. It was found that it was suppressed (see FIG. 9).
- NO and PGEs are synthesized from L-arginine and phospholipids by nitric oxide synthase (NOS) and cyclooxygenase (COX), respectively. Excessive increases in NO and PGE2 under pathological conditions stimulate the inflammatory process and synergize with other inflammatory mediators. Under these conditions, excess NO and PGE2 are synthesized by inducible NOS (iNOS) and COX-2. In addition, iNOS and COX-2 are strongly expressed when exposed to inflammatory cytokines and bacterial endotoxins.
- NOS nitric oxide synthase
- COX cyclooxygenase
- NF- ⁇ B is normally inactivated in the cytoplasm by binding to inhibitory ⁇ B- ⁇ (I ⁇ B- ⁇ ).
- I ⁇ B- ⁇ inhibitory ⁇ B- ⁇
- NF- ⁇ B in the inactivated state of the cell is activated by phosphorylation and migrates into the nucleus, thereby contributing to transcription of inflammation-related proteins.
- the present inventors mixed the feed sawn bar alcohol extract with feed for 19 days in experimental animals induced by CIA treatment in order to determine whether the toothed barn alcohol extract of the present invention affects the transfer of NF- ⁇ B into the nucleus. suddenly. Tissue lysates were obtained for each animal group used in the experiment, followed by Western blot using an antibody against NF- ⁇ B phosphorylation.
- NF- ⁇ B phosphorylation induced by CIA treatment was reduced in concentration-dependent manner by the feeding of the cogwheel extract of Sawtooth Maban, and the phosphorylation level was similar to that of the control by the feeding of 0.05% alcohol extract. Levels were indicated.
- the sawtooth maternal ethanol extract inhibits the phosphorylation of NF- ⁇ B in the joint tissues of experimental animals induced by CIA treatment, whereby NF- ⁇ B moves to the nucleus and acts as an inflammatory factor such as inflammatory cytokines.
- Experimental animals were able to block the activation of.
- Molecular signal transduction mechanisms that regulate the process of inducing the expression of iNOS, COX-2 or proinflammatory cytokines through activation of NF- ⁇ B transcription factors by various external stimuli are three enzymes belonging to the major MAPK subfamily: extracellular-regulated protein kinase (ERK), c-Jun NH2-protein kinase (JNK), p38 MAPK and PI3K / Akt.
- ERK extracellular-regulated protein kinase
- JNK c-Jun NH2-protein kinase
- p38 MAPK p38 MAPK
- PI3K / Akt PI3K / Akt.
- sawtooth maize alcohol extract showed the inhibition of phosphorylation (activation) of Akt, JNK, p38 MAPK. Therefore, it was found from the above results that the sawtooth cap ethanol extract inhibits the inflammatory response by blocking various signal protein pathways in the joint tissue.
- Induction of rheumatoid arthritis with CIA increases the expression of MMP-1, MMP-2 and MMP-9 that break down cartilage tissue at the joint site, increases MCP-1 inducing inflammatory cell infiltration into articular synovial tissue, and joints Increasing ICAM-1 and VCAM-1 increase the invasion of inflammatory cells in the synovial tissue of.
- the western blot was performed to confirm the effect of the sawtooth maternal ethanol extract of the present invention on the inhibitory effect of ICAM-1, VCAM-1, MCP-1, MMP-1, 2, 9 in the joint inflammation site.
- the expression level of TNF- ⁇ in various inflammatory cytokines was measured using an ELISA kit.
- the sawtooth mother extract of the present invention showed that the arthritis treatment effect is superior to other mother and child extracts.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims (6)
- 톱니모자반 추출물(Sargassum serratifolium)을 유효성분으로 포함하는 관절염 예방 또는 치료용 약학적 조성물.
- 제1항에 있어서,상기 톱니모자반 추출물은 물 또는 유기용매를 이용하여 수득한 추출물인 것을 특징으로 하는 조성물.
- 제2항에 있어서,상기 유기용매는 메탄올, 에탄올, 프로판올, 이소프로판올, 부탄올, 아세톤, 에테르, 벤젠, 클로로포름, 에틸아세테이트, 메틸렌클로라이드, 헥산 및 시클로헥산으로 이루어진 군 중에서 선택되는 것을 특징으로 하는 조성물.
- 제1항에 있어서,상기 톱니모자반 추출물은 염증성 사이토카인 IL-1β, IL-6 또는 TNF-a의 활성을 감소 또는 억제하는 것을 특징으로 하는 조성물.
- 제1항에 있어서,상기 관절염은 퇴행성 관절염, 류마티스 관절염 또는 루푸스(Lupus) 관절염인 것을 특징으로 하는 조성물.
- 톱니모자반 추출물(Sargassum serratifolium)을 유효성분으로 포함하는 관절염 예방 또는 개선용 건강기능식품.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018514752A JP6539780B2 (ja) | 2015-10-30 | 2016-02-11 | ウスバノコギリモク抽出物を有効成分として含む関節炎予防または治療用組成物 |
US15/578,200 US10286021B2 (en) | 2015-10-30 | 2016-02-11 | Composition for prevention or treatment of arthritis, containing Sargassum serratifolium extract as active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2015-0152164 | 2015-10-30 | ||
KR1020150152164A KR101783525B1 (ko) | 2015-10-30 | 2015-10-30 | 톱니모자반 추출물을 유효성분으로 포함하는 관절염 예방 또는 치료용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017073849A1 true WO2017073849A1 (ko) | 2017-05-04 |
Family
ID=58631646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2016/001371 WO2017073849A1 (ko) | 2015-10-30 | 2016-02-11 | 톱니모자반 추출물을 유효성분으로 포함하는 관절염 예방 또는 치료용 조성물 |
Country Status (4)
Country | Link |
---|---|
US (1) | US10286021B2 (ko) |
JP (1) | JP6539780B2 (ko) |
KR (1) | KR101783525B1 (ko) |
WO (1) | WO2017073849A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10286021B2 (en) | 2015-10-30 | 2019-05-14 | Pukyong National University Industry-University Cooperation Foundation | Composition for prevention or treatment of arthritis, containing Sargassum serratifolium extract as active ingredient |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101947276B1 (ko) * | 2017-08-07 | 2019-02-12 | 부경대학교 산학협력단 | 큰잎모자반 효소 분해물을 유효성분으로 함유하는 면역 증강용 조성물 |
KR101998511B1 (ko) * | 2018-01-29 | 2019-07-09 | 동의대학교 산학협력단 | 톱니모자반 추출물을 포함하는 골다공증 예방 또는 치료용 조성물 |
KR20200144849A (ko) | 2019-06-19 | 2020-12-30 | 국립해양생물자원관 | 톱니모자반 추출물을 포함하는 비용종 질환 예방 또는 치료용 조성물 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100131809A (ko) * | 2009-06-08 | 2010-12-16 | 재단법인 제주테크노파크 | 항염증성 조성물 |
KR101057007B1 (ko) * | 2011-01-26 | 2011-08-16 | 한국해양연구원 | 꽈배기모자반(Sargassum siliquastrum) 추출물을 포함하는 염증성 질환의 예방 및 치료용 약학적 조성물 |
KR20110118064A (ko) * | 2010-04-22 | 2011-10-28 | 재단법인 제주테크노파크 | 잔가시모자반으로부터 분리한 활성물질을 이용한 항염증성 조성물 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008153748A1 (en) * | 2007-05-24 | 2008-12-18 | The Mclean Hospital Corporation | Methods and compositions for the use of sargassum fusiforme for the inhibition of hiv-1 infection |
JP6049639B2 (ja) * | 2011-12-28 | 2016-12-21 | マルハニチロ株式会社 | クロロフィルc含有脱顆粒抑制剤 |
KR101783525B1 (ko) | 2015-10-30 | 2017-10-10 | 부경대학교 산학협력단 | 톱니모자반 추출물을 유효성분으로 포함하는 관절염 예방 또는 치료용 조성물 |
-
2015
- 2015-10-30 KR KR1020150152164A patent/KR101783525B1/ko active IP Right Grant
-
2016
- 2016-02-11 US US15/578,200 patent/US10286021B2/en active Active
- 2016-02-11 WO PCT/KR2016/001371 patent/WO2017073849A1/ko active Application Filing
- 2016-02-11 JP JP2018514752A patent/JP6539780B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100131809A (ko) * | 2009-06-08 | 2010-12-16 | 재단법인 제주테크노파크 | 항염증성 조성물 |
KR20110118064A (ko) * | 2010-04-22 | 2011-10-28 | 재단법인 제주테크노파크 | 잔가시모자반으로부터 분리한 활성물질을 이용한 항염증성 조성물 |
KR101057007B1 (ko) * | 2011-01-26 | 2011-08-16 | 한국해양연구원 | 꽈배기모자반(Sargassum siliquastrum) 추출물을 포함하는 염증성 질환의 예방 및 치료용 약학적 조성물 |
Non-Patent Citations (2)
Title |
---|
JOUNG, E. -J. ET AL.: "Anti-inflammatory Effect of Sargachromenol Isolated from Sargasium Serratifolium on Lipopolysaccharide-induced Nitric Oxide and Prostaglandin E2 in Raw 264.7 Macrophages", CONFERENCE OF THE KOREAN FEDERATION OF FISHERIES SCIENCE AND TECHNOLOGY SOCIETIES, BOOK OF ABSTRACTS, May 2015 (2015-05-01), pages 239 * |
KUSUMI, T. ET AL.: "Structures of New Plastoquinones from the Brown Alga Sarcassum Serratifolium", CHEMISTRY LETTERS, vol. 8, no. 3, 1979, pages 277 - 278, XP002938987 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10286021B2 (en) | 2015-10-30 | 2019-05-14 | Pukyong National University Industry-University Cooperation Foundation | Composition for prevention or treatment of arthritis, containing Sargassum serratifolium extract as active ingredient |
Also Published As
Publication number | Publication date |
---|---|
US10286021B2 (en) | 2019-05-14 |
KR101783525B1 (ko) | 2017-10-10 |
JP2018516986A (ja) | 2018-06-28 |
US20180221424A1 (en) | 2018-08-09 |
KR20170050523A (ko) | 2017-05-11 |
JP6539780B2 (ja) | 2019-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017073849A1 (ko) | 톱니모자반 추출물을 유효성분으로 포함하는 관절염 예방 또는 치료용 조성물 | |
WO2017176082A1 (ko) | 익지 추출물을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물 | |
WO2017183902A1 (ko) | 인진, 지유 및 울금 추출물 및 항바이러스제를 유효성분으로 포함하는 간질환 예방 또는 치료용 조성물 | |
WO2020256464A1 (ko) | 항염 활성을 갖는 아피오스 아메리카나 괴경 추출물의 분획물의 알코올성 위염 예방 또는 치료제로서의 용도 및 이의 제조방법 | |
KR101899555B1 (ko) | 노각나무 추출물 및 옻나무 추출물을 함유하는 관절염의 개선, 예방 또는 치료용 조성물 | |
WO2014133286A1 (ko) | 한인진 및 울금의 추출물을 유효성분으로 포함하는 비만 관련 질환의 예방, 억제 또는 치료용 조성물 | |
KR101257494B1 (ko) | 전복 소화 가수분해물을 함유하는 면역계 염증성 질환 예방 및 치료용 조성물 | |
WO2011019153A2 (ko) | 오미자, 황금 및 해동피의 혼합 생약재 추출물을 유효성분으로 포함하는 관절염 예방 또는 치료용 조성물 | |
KR101332824B1 (ko) | 민대극 추출물을 포함하는 관절염 예방 및 치료용 조성물 | |
KR102352936B1 (ko) | 톱니모자반 추출물을 포함하는 염증성 장질환의 예방 또는 치료용 조성물 | |
KR102545762B1 (ko) | 세모가사리 추출물을 유효성분으로 포함하는 골관절염의 예방 또는 치료용 조성물 | |
KR100760386B1 (ko) | Acp 혼합생약 추출물을 포함하는 관절염의 예방 및 치료용 조성물 | |
WO2018066952A1 (ko) | 관중 추출물을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물 | |
WO2023224305A1 (ko) | 갯까치수염 추출물을 유효성분으로 함유하는 관절염 및 관절통증의 예방, 개선 또는 치료용 조성물 | |
WO2019083264A1 (ko) | 숙성새싹삼 추출물의 발효물을 유효성분으로 함유하는 간질환의 예방, 개선 또는 치료용 조성물 | |
KR20140089315A (ko) | 갯방풍 추출물을 유효성분으로 포함하는 관절염 예방 또는 치료용 조성물 | |
WO2023121314A1 (ko) | 알코올성 간 손상 또는 알코올성 뇌 손상 보호를 위한 아피오스 아메리카나 괴경 추출물의 용도 | |
KR101887585B1 (ko) | 암브로시아 아르테미시폴리아 추출물 또는 이의 분획물을 유효성분으로 포함하는 인지기능 장애 또는 신경 염증의 예방 또는 치료용 조성물 | |
KR20200045811A (ko) | 사가하이드로퀴노익산을 포함하는 관절염 예방 또는 치료용 조성물 | |
KR102496753B1 (ko) | 좁쌀풀 추출물을 유효성분으로 포함하는 인지기능장애 예방 또는 치료용 조성물 | |
KR102507333B1 (ko) | 악테오사이드를 포함하는 약학적 조성물 및 건강기능식품 | |
WO2023063663A1 (ko) | 베타-구아니디노프로피온산을 포함하는 간섬유화 예방 또는 치료용 조성물 | |
WO2023121334A1 (ko) | 황새냉이 추출물을 유효성분으로 함유하는 호흡기 질환의 예방, 개선 또는 치료용 조성물 | |
KR102037531B1 (ko) | 왕귀뚜라미 추출물을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 | |
WO2014163413A1 (ko) | 인삼열매 추출물을 포함하는 수명 연장용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16860033 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018514752 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15578200 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16860033 Country of ref document: EP Kind code of ref document: A1 |